Skip to Content

Dapagliflozin / saxagliptin Pregnancy and Breastfeeding Warnings

Dapagliflozin / saxagliptin is also known as: Qtern

Dapagliflozin / saxagliptin Pregnancy Warnings

Not recommended US FDA pregnancy category: Not Assigned Comments: -If pregnancy is detected, this drug should be discontinued. -Poorly controlled diabetes is a risk to both the mother and fetus therefore, alternative therapy will be necessary to control blood sugars.

Animal studies with saxagliptin have shown reproductive toxicity at high doses; rat studies with dapagliflozin have shown toxicity to the developing kidney in the time period corresponding to the second and third trimesters of human pregnancy. There are no adequate and well controlled studies in pregnant women from the use of this combination product. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Dapagliflozin / saxagliptin Breastfeeding Warnings

Not recommended Excreted into human milk: Dapagliflozin (unknown); Saxagliptin (unknown) Excreted into animal milk: Dapagliflozin (yes); Saxagliptin (yes) The effects in the nursing infant are unknown.

Juvenile rats exposed to dapagliflozin showed a risk of renal pelvic and tubular dilations during maturation. Since kidney maturation occurs during the first 2 years of life, there may be a risk to the developing kidney of the breastfed infant.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Qtern (dapagliflozin-saxagliptin)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Qtern (dapagliflozin-saxagliptin)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide